Related Experiment Video
Updated: Jul 22, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson's disease
Hisashi Uwatoko1, Yuka Hama2, Ikuko Takahashi Iwata2
1Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8368, Japan. uwatoko@pop.med.hokudai.ac.jp.
Abstract:
MicroRNAs (miRNAs) are endogenous small (18-25 nt), single-stranded, non-coding RNAs that play key roles in post-transcriptional gene expression regulation. The expression profiles of miRNAs in biofluids and tissues change in various diseases. Multiple system atrophy (MSA) and Parkinson's disease (PD) are both categorized as α-synucleinopathies and often present with similar clinical manifestations. This study aimed to identify miRNAs that are differently expressed in plasma samples of PD patients, MSA patients, and healthy controls. We used microarray analysis to screen for miRNAs that are up- and down-regulated in these patients and analyzed the relative-quantitative expression levels of the identified miRNAs by reverse transcription quantitative polymerase chain reaction (RT-qPCR). Hsa-miR-671-5p, hsa-miR-19b-3p, and hsa-miR-24-3p showed significantly different expression levels among patients with MSA-C, MSA-P, or PD, and healthy controls. Hsa-miR-671-5p levels were lower in the MSA-P and PD than the MSA-C and control groups, hsa-miR-19b-3p levels were higher in the PD than the other groups, and hsa-miR-24-3p levels were higher in the PD than the MSA-C group. Hsa-miR-671-5p was the first miRNA shown to be expressed differently between MSA-C and MSA-P in plasma. Interestingly, the expression levels of hsa-miR-19b-3p and hsa-miR-24-3p were positively correlated, indicating that these miRNAs may be involved in the same processes in PD pathogenesis. Our findings suggest that hsa-miR-671-5p, hsa-miR-19b-3p, and hsa-miR-24-3p may reflect the pathophysiology or symptoms of PD and MSA.
Insights
This study identified distinct microRNA (miRNA) profiles in Parkinson's disease (PD) and Multiple System Atrophy (MSA) patients. Specific miRNAs in plasma may help differentiate these neurodegenerative diseases.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- MicroRNAs (miRNAs) are crucial regulators of gene expression, and their dysregulation is implicated in various diseases.
- Multiple System Atrophy (MSA) and Parkinson's disease (PD) are α-synucleinopathies with overlapping clinical symptoms, necessitating reliable biomarkers for differentiation.
Purpose of the Study:
- To identify differentially expressed miRNAs in the plasma of patients with PD, MSA (cerebellar and postural subtypes), and healthy controls.
- To explore the potential of these miRNAs as biomarkers for distinguishing between PD and MSA subtypes.
Main Methods:
- Plasma samples were analyzed using microarray analysis to screen for differentially expressed miRNAs.
- Quantitative expression levels of candidate miRNAs were validated using reverse transcription quantitative polymerase chain reaction (RT-qPCR).
Main Results:
- Significant differences in plasma levels of hsa-miR-671-5p, hsa-miR-19b-3p, and hsa-miR-24-3p were observed among the groups.
- Hsa-miR-671-5p levels were lower in MSA-P and PD compared to MSA-C and controls, distinguishing MSA subtypes.
- Hsa-miR-19b-3p and hsa-miR-24-3p showed higher expression in PD, with a positive correlation between them.
Conclusions:
- Hsa-miR-671-5p, hsa-miR-19b-3p, and hsa-miR-24-3p are potential plasma biomarkers for differentiating PD and MSA.
- These miRNAs may reflect the underlying pathophysiology or clinical symptoms of these α-synucleinopathies.
Related Concept Videos
Neural Regulation
Parkinson Disease ll: Pathophysiology
Alterations in Muscle Tone lll

